11/18
08:50 am
idya
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is now covered by analysts at Stephens. They set an "overweight" rating and a $51.00 price target on the stock.
Low
Report
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is now covered by analysts at Stephens. They set an "overweight" rating and a $51.00 price target on the stock.
11/18
06:10 am
idya
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer [Yahoo! Finance]
Low
Report
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer [Yahoo! Finance]
11/18
06:00 am
idya
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
Low
Report
IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer
11/12
06:00 am
idya
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day
Medium
Report
IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day
11/11
06:00 am
idya
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
Low
Report
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
11/11
06:00 am
idya
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
Low
Report
Biocytogen Announces IDEAYA’s Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise
11/11
06:00 am
idya
IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen
Low
Report
IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen
11/6
06:32 am
idya
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Medium
Report
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
11/5
07:27 am
idya
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $27.00 price target on the stock.
Low
Report
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) was downgraded by analysts at Leerink Partners from an "outperform" rating to a "market perform" rating. They now have a $27.00 price target on the stock.
11/5
06:13 am
idya
IDEAYA Biosciences Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023) [Yahoo! Finance]
Low
Report
IDEAYA Biosciences Third Quarter 2024 Earnings: US$0.60 loss per share (vs US$0.46 loss in 3Q 2023) [Yahoo! Finance]
11/5
12:45 am
idya
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $52.00 price target on the stock.
Low
Report
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $52.00 price target on the stock.
11/4
06:15 am
idya
IDEAYA Biosciences GAAP EPS of -$0.60 beats by $0.04 [Seeking Alpha]
Medium
Report
IDEAYA Biosciences GAAP EPS of -$0.60 beats by $0.04 [Seeking Alpha]
11/4
06:00 am
idya
IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update
11/1
06:00 am
idya
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
10/29
12:22 pm
idya
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $53.00 price target on the stock.
Low
Report
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $53.00 price target on the stock.
10/28
06:00 am
idya
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors
Low
Report
IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors
10/25
06:00 am
idya
IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024
Low
Report
IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024
10/24
07:16 am
idya
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $50.00 price target on the stock.
Low
Report
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $50.00 price target on the stock.
10/20
07:23 pm
idya
Exploring High Growth Tech Stocks In Hong Kong [Yahoo! Finance]
Low
Report
Exploring High Growth Tech Stocks In Hong Kong [Yahoo! Finance]
10/15
09:02 am
idya
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Low
Report
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
10/4
06:00 am
idya
IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium
Low
Report
IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium
9/27
06:00 am
idya
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
9/24
02:05 pm
idya
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its price target lowered by analysts at Wedbush from $54.00 to $52.00. They now have an "outperform" rating on the stock.
Low
Report
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its price target lowered by analysts at Wedbush from $54.00 to $52.00. They now have an "outperform" rating on the stock.
9/24
09:14 am
idya
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $61.00 price target on the stock.
Medium
Report
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $61.00 price target on the stock.
9/24
08:44 am
idya
IDEAYA's rare cancer drug shows promise as company lays out Phase III plans [Yahoo! Finance]
Medium
Report
IDEAYA's rare cancer drug shows promise as company lays out Phase III plans [Yahoo! Finance]